ReviewRespirology (Carlton, Vic.)2010
Current development and future prospects in chemotherapy of tuberculosis.
Review in Respirology (Carlton, Vic.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03561753 (Pilot Clinical Trial of PRS TB Regimen I - Phase II), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Clinical Trial of PRS TB Regimen I - Phase II
Who cites it
22 citing papers in PubMed.
- Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2013Trial
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel, Switzerland) · 2022Review
- Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review.Pharmaceutics · 2021Review
- Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy AgainstFrontiers in immunology · 2019Article
- Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.Nature communications · 2017Article
- Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.Antimicrobial agents and chemotherapy · 2016Article
- Rifamycins, Alone and in Combination.Cold Spring Harbor perspectives in medicine · 2016Review
- Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The role of delamanid in the treatment of drug-resistant tuberculosis.Therapeutics and clinical risk management · 2015Review
- Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis.Journal of chemical information and modeling · 2014Article
- Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model.PloS one · 2014Article
- Recent advances in tuberculosis: New drugs and treatment regimens.Current respiratory medicine reviews · 2013Article
- Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.Chemistry & biology · 2013Article
- TB Mobile: a mobile app for anti-tuberculosis molecules with known targets.Journal of cheminformatics · 2013Article
- Mechanisms of Pyrazinamide Action and Resistance.Microbiology spectrum · 2013Article
- Antituberculosis therapy for 2012 and beyond.Expert opinion on pharmacotherapy · 2012Review
- Article
- Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.Science (New York, N.Y.) · 2011Article
- Epidemiology of tuberculosis and HIV: recent advances in understanding and responses.Proceedings of the American Thoracic Society · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although treatment of drug-susceptible tuberculosis (TB) under ideal conditions may be successful in >or=95% of cases, cure rates in the field are often significantly lower due to the logistical challenges of administering and properly supervising the intake of combination chemotherapy for 6-9 months. Success rates are far worse for multidrug-resistant and extensively drug-resistant TB cases. There is general agreement that new anti-TB drugs are needed to shorten or otherwise simplify treatment for drug-susceptible and multidrug-resistant/extensively drug-resistant-TB, including TB associated with HIV infection. For the first time in over 40 years, a nascent pipeline of new anti-TB drug candidates has been assembled. Eleven candidates from seven classes are currently being evaluated in clinical trials. They include novel chemical entities belonging to entirely new classes of antibacterials, agents approved for use against infections other than TB, and an agent already approved for limited use against TB. In this article, we review the current state of TB treatment and its limitations and provide updates on the status of new drugs in clinical trials. In the conclusion, we briefly highlight ongoing efforts to discover new compounds and recent advances in alternative drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.